Peter Weingold, MD
Psychiatry · Los Angeles, CANPI 1740202035
Payments from drug & device makers
Across 314 payments — averaging $21.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Lundbeck LLC$1K
- AbbVie$1K
- Sunovion Pharmaceuticals Inc.$575
- Otsuka America Pharmaceutical, Inc.$484
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$482
- plus $1K from 16 others
What the payments were for
- Food & beverage$6,807100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 66 | $1,522 |
| Lundbeck LLC | 60 | $1,360 |
| AbbVie(2 entities) | 59 | $1,292 |
| Sunovion Pharmaceuticals Inc. | 31 | $575 |
| Otsuka America Pharmaceutical, Inc. | 24 | $484 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 24 | $482 |
| Johnson & Johnson | 9 | $223 |
| Axsome Therapeutics, Inc. | 6 | $160 |
| Bausch Health US, LLC | 7 | $115 |
| Idorsia Pharmaceuticals US Inc | 6 | $100 |
| Merck | 3 | $65 |
| Alkermes, Inc. | 2 | $57 |
| Neurocrine Biosciences, Inc. | 2 | $55 |
| Almatica Pharma LLC | 3 | $52 |
| Vanda Pharmaceuticals Inc. | 2 | $50 |
| Noven Therapeutics, LLC | 2 | $42 |
| Neos Therapeutics, LP | 2 | $42 |
| Vertical Pharmaceuticals, LLC | 2 | $37 |
| E.r. Squibb & Sons, L.L.C. | 1 | $26 |
| Novo Nordisk | 1 | $24 |
| Eisai Inc. | 1 | $24 |
| Arbor Pharmaceuticals, Inc. | 1 | $21 |
How this compares
$6,807 in reported general payments places this provider in the 90th percentile of 4,954 psychiatry providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 29 | $41,044 |
| TrintellixVortioxetine Hydrobromide | 23 | $20,255 |
| CaplytaLumateperone Tosylate | 11 | $17,327 |
| Aripiprazole | 60 | $12,858 |
| VyvanseLisdexamfetamine Dimesylate | 15 | $5,652 |
| Lisdexamfetamine Dimesylate | 22 | $5,623 |
| ConcertaMethylphenidate Hcl | 13 | $5,555 |
| SeroquelQuetiapine Fumarate | 17 | $3,719 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 96 | $3,380 |
| Bupropion XlBupropion Hcl | 140 | $2,900 |
| Methylphenidate ErMethylphenidate Hcl | 18 | $2,203 |
| Lurasidone Hcl | 15 | $1,492 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 37 | $1,484 |
| Vilazodone Hcl | 20 | $1,432 |
| Duloxetine Hcl | 29 | $1,401 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $484 | $41,04429 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $1,522 | $25,90738 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $482 | $17,32711 claims |
| Johnson & JohnsonConcerta | $223 | $5,55513 claims |
| Almatica Pharma LLCSertraline Hcl | $52 | $70959 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,954 psychiatry providers in California.
Other psychiatry in Los Angeles
- Lon SchneiderLos Angeles$1.8M
- Elly LeeIrvine$49.8M
- Daniel ChuehOrange$17.9M
- Eric ChavezSan Diego$15.5M
- Lara ShirikjianTorrance$12.6M
- John DuffySanta Ana$12M
- Marina BusselPlaya Vista$12M
- Sherry SoefjeOceanside$11.9M
- Steven MacinaHuntington Beach$11.1M
- Wakelin McNeelRosemead$11M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.